Company news

H. Lundbeck A/s Class A (OMXCOP:HLUN_A) news

Every H. Lundbeck A/s Class A press release and news update in one place — announcements, filings coverage, and company updates for investors.

View H. Lundbeck A/s Class A stock analysis →

Press releases & updates

Lundbeck receives orphan drug designation in the US and EU for Lu AG13909 for the treatment of patients with congenital adrenal hyperplasia

June 24, 2025

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

June 21, 2025